Schnaper H W, Freis E D, Friedman R G, Garland W T, Hall W D, Hollifield J, Jain A K, Jenkins P, Marks A, McMahon F G
Center for Aging, University of Alabama, Birmingham 35294.
Arch Intern Med. 1989 Dec;149(12):2677-81.
Among 447 hypertensive patients, most with a history of diuretic-induced hypokalemia, 252 developed diuretic-induced hypokalemia while receiving hydrochlorothiazide, 50 mg/d. In a randomized study we evaluated the efficacy of three drug regimens in restoring potassium levels while maintaining blood pressure control: hydrochlorothiazide (50 mg/d) plus potassium supplement (20 mmol/d); hydrochlorothiazide (50 mg/d) plus potassium supplement (40 mmol/d); or hydrochlorothiazide (50 mg/d) with triamterene (75 mg/d) in one combination tablet. In all groups, mean serum levels of potassium rose within 1 week and showed no further change thereafter. However, the hydrochlorothiazide/triamterene and hydrochlorothiazide plus 40 mmol of potassium regimens were significantly more effective in restoring serum potassium levels than was the hydrochlorothiazide plus 20 mmol of potassium regimen. A significant increase in magnesium levels was observed only in the group treated with the hydrochlorothiazide/triamterene combination. Each regimen provided continued control of mild to moderate hypertension.
在447名高血压患者中,大多数有因利尿剂导致低钾血症的病史,其中252名患者在接受每日50毫克氢氯噻嗪治疗时出现了利尿剂诱发的低钾血症。在一项随机研究中,我们评估了三种药物治疗方案在维持血压控制的同时恢复血钾水平的疗效:氢氯噻嗪(每日50毫克)加补钾剂(每日20毫摩尔);氢氯噻嗪(每日50毫克)加补钾剂(每日40毫摩尔);或氢氯噻嗪(每日50毫克)与氨苯蝶啶(每日75毫克)制成的复方片剂。在所有组中,血钾平均水平在1周内上升,此后未再出现变化。然而,氢氯噻嗪/氨苯蝶啶组和氢氯噻嗪加40毫摩尔钾治疗方案在恢复血钾水平方面比氢氯噻嗪加20毫摩尔钾治疗方案显著更有效。仅在氢氯噻嗪/氨苯蝶啶联合治疗组中观察到镁水平显著升高。每种治疗方案都能持续控制轻度至中度高血压。